PERTH, Australia, Dec. 13, 2021 /PRNewswire/ -- Advanced
Human Imaging Limited (ASX:AHI) (NASDAQ:AHI) ("AHI" or the
"Company") is pleased to announce the signing of a binding term
sheet with NEXTMEDICALL S.A.C ("Nextmedicall"), a
Peruvian-based telemedicine company.
Nextmedicall offers reliable care from the comfort of a
patient's home with teleconsultation for all medical specialties
through the platforms extensive network of doctors and specialists.
Pursuant to the binding term sheet, Nextmedicall will integrate the
AHI MultiScan Software Development Kit into the Nextmedicall
platform. The initial integration will allow access to AHI's
proprietary BodyScan and FaceScan with the intention to add
DermaScan, HemaScan and other offerings from AHI once released in
The integration will allow Nextmedicall users to track and
ascertain dimensional-based risk assessments and vital signs prior
to and during telehealth consultation. Nextmedicall will leverage
the partnership to identify early onset chronic disease markers and
chronic disease risk for early intervention and provision of care
across Latin America.
Nextmedicall conducted due diligence of the AHI CompleteScan
platform prior to signing the binding term sheet with AHI and is
currently running a pilot program with Chilean Telecommunications
provider Entel Chile.
"I am pleased to expand the AHI offering into Latin America with Nextmedicall. The scope of
their medical team and offering is significant and it will help us
deliver our solution to a large population in need of
cost-effective care," said Vlado
Bosanac, Chief Executive Officer of Advanced Human Imaging.
"The Nextmedicall team has a deep understanding of the
telecommunications industry and the need to deliver more value to
patients of these services. Through this partnership, Nextmedicall
wishes to triage patients into early intervention and care. This
will reduce the need for episodic care, through early diagnosis and
intervention that results in better health outcomes."
Nextmedicall will commence integration of the AHI technology
into the Nextmedicall platform in a white-label solution within 120
days from the signing of the binding term sheet.
About Advanced Human Imaging:
AHI has developed and patented a proprietary dimensioning
technology that enables its users to check, track, and assess their
dimensions in conjunction with known health risk indicators using
only a smartphone both privately and accurately.
Our goal is to assist our partners by empowering their consumers
with this capability. This in return gives our partners the ability
to assess, assist, and communicate outcomes with their consumers
when navigating day to day life. Whether this is a personal journey
to better health, understanding the risk associated with their
physical condition, tracking the changes they are experiencing
through training, dieting, or under medical regimes, or simply
wanting to be correctly sized for a garment when shopping online.
The AHI technology delivers this seamlessly, privately, and
cost-effectively in under one minute.
AHI has developed this capability by leveraging the power of
Computer Vision, Machine Learning, and patented algorithms, to
process the images and assessments on secure, enterprise-level
infrastructure, delivering an end–to–end experience that is
unrivalled in the industry. AHI simplifies the collection of
measurements and removes the human error present in traditional
Forward Looking Statements
This press release contains certain forward-looking statements,
including those relating to the regarding the use of proceeds and
other statements that are predictive in nature. Forward-looking
statements are based on the Company's current expectations and
assumptions. The Private Securities Litigation Reform Act of 1995
provides a safe-harbor for forward-looking statements. These
statements may be identified by the use of forward-looking
expressions, including, but not limited to, 'expect,' 'anticipate,'
'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,'
'project,' 'should,' 'would' and similar expressions and the
negatives of those terms. Prospective investors are cautioned not
to place undue reliance on such forward-looking statements, which
speak only as of the date of this presentation. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Important factors that could cause actual results to
differ materially from those in the forward-looking statements are
set forth in the Company's filings with the Securities and Exchange
Commission, including its registration statement on Form F-1, as
amended from time to time, under the caption 'Risk Factors.'
For more information please
For more information contact:
View original content to download
SOURCE Advanced Human Imaging